Coherus Oncology (CHRS) Current Assets (2013 - 2026)

Coherus Oncology has disclosed Current Assets across 14 years of filings, most recently posting $133.8 million for Q2 2026.

• In Q2 2026, Current Assets fell 64.81% year-over-year to $133.8 million; the TTM figure through Jun 2026 stood at $133.8 million (down 64.81% YoY), while the FY2025 annual figure was $206.7 million, down 39.49% from the prior year.
• Current Assets came in at $133.8 million for Q2 2026 at Coherus Oncology, down from $206.0 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $627.5 million in Q1 2024 to a low of $133.8 million in Q2 2026.
• Average Current Assets over 5 years is $389.1 million, with a median of $383.4 million recorded in 2022.
• Year-over-year, Current Assets surged 98.62% in 2024 and plunged 64.81% in 2026.
• Over 5 years, Current Assets stood at $381.2 million in 2022, then advanced by 24.76% to $475.6 million in 2023, then dropped by 28.18% to $341.6 million in 2024, then plunged by 39.49% to $206.7 million in 2025, then plunged by 35.28% to $133.8 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $133.8 million in Q2 2026, $206.0 million in Q1 2026, and $206.7 million in Q4 2025.